Vasculitis
Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data will be presented on options for GCA.

David Liew drdavidliew
3 years 11 months ago
In GCA, why might you target GM-CSF over IL-6?
Entirely plausible TCZ might be leaving some Th1 stones unturned, esp:
vascular remodelling
downreg pathways
Transcriptomics from toci/mavri-treated TAB show it's plausible beyond just theory...
Cid group #ACR21 ABST0506 @RheumNow https://t.co/YephlzHOdj


Janet Pope Janetbirdope
3 years 11 months ago
Do you use ANCA to change Rx in prevalent GPA pts? GS401 #ACR21 @RheumNow

Richard Conway RichardPAConway
3 years 11 months ago
Dr De Miguel on subclinical large vessel vasculitis in PMR. US assessment. 22% had subclinical GCA. 90% LVV, 10% cranial GCA. Abstr#0466 #ACR21 @RheumNow https://t.co/PDCynMAigi


Richard Conway RichardPAConway
3 years 11 months ago
Our latest article on outcomes of patients with vasculitis and PMR and COVID-19 published in @TheLancetRheum . @rheum_covid project with co-leads @SattuiSEMD and @EBRheum . https://t.co/8NTAafdYRA

Nina Couette RheumDr_Nina
3 years 11 months ago
📌Pre-Test Probability in GCA
ESR/CRP can be normal:
~10% of pts at diagnosis
-20-40% at time or relapse
#ACR21 #ACRAmbassador #RheumTwitter https://t.co/kenaD31pYa


Richard Conway RichardPAConway
3 years 11 months ago
Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Most MPO+, but also rarely seen with PR3+. 47% ⬆️ risk of death. Abstr#0430 #ACR21 @RheumNow https://t.co/6MnxqW92bz


Richard Conway RichardPAConway
3 years 11 months ago
Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ


David Liew drdavidliew
3 years 11 months ago
How much ritux for AAV maintenance?
Ever since we started using it, no-one's been sure.
If absolute B cell depletion is your goal, @VUMCRheum data suggest >3.3mg/d is safest for that
500mg q6m = 2.7 mg/d
500mg q4m = 4.1 mg/d
1000mg q6m = 5.5mg/d
#ACR21 ABST0416 @RheumNow https://t.co/mYAgKhHT7j


Richard Conway RichardPAConway
3 years 11 months ago
Dr Springer on pharmacological response of RTX in ANCA-vasculitis. Suggest that 500mg every 6 months may not achieve sufficient B cell depletion in all. What are the clinical implications? Is anyone dosing 500mg as standard? Abstr#0416 #ACR21 @RheumNow https://t.co/w36hSYbW1B


David Liew drdavidliew
3 years 11 months ago
In ANCA-associated vasculitis, does reverse seroconverting (ANCA+➡️ANCA-) make a difference?
relapse - no
ESRD - no
death - no
Don't measure serial ANCAs for prognosis
(no diff MPO/PR3, RTX/CYC)
target trial emulation @BrighamWomens @MGHrheumatology #ACR21 ABST0419 @RheumNow https://t.co/rLkTY0ul8f


Eric Dein ericdeinmd
3 years 11 months ago
ADVOCATE - Avacopan: C5a inhibitor, promising new therapy for ANCA vasculitis as possible steroid sparing therapy. Non-inferior outcome of remission, sustained remission, relapse wo signif adverse effects. @rheumnow #ACR21 https://t.co/m5zexRpeS8


sheila RHEUMarampa
3 years 11 months ago
#ACR21 #YearinReview
Avacopan: The game changer for ANCA #vasculitis?🧐
🔅Remission at wk 26: Avacopan non-inferior to Pred (72.3% vs. 70.1%, p<0.001)
🔅Sustained remission at wk 56: Avacopan non-inferior to Pred (65.7% vs. 54.9%, p<0.001)
@RheumNow
https://t.co/CpPYVvRoMR https://t.co/QnsZIUQ0uu
